CO5290258A1 - Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados - Google Patents

Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados

Info

Publication number
CO5290258A1
CO5290258A1 CO01013781A CO01013781A CO5290258A1 CO 5290258 A1 CO5290258 A1 CO 5290258A1 CO 01013781 A CO01013781 A CO 01013781A CO 01013781 A CO01013781 A CO 01013781A CO 5290258 A1 CO5290258 A1 CO 5290258A1
Authority
CO
Colombia
Prior art keywords
phenyl
optionally substituted
alkyl
independently selected
group
Prior art date
Application number
CO01013781A
Other languages
English (en)
Inventor
Roger Bonnert
Stewart Gardiner
Fraser Hunt
Walters Ian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5290258A1 publication Critical patent/CO5290258A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Abstract

Un compuesto de la fórmula (I) o una sal o solvato del mismo farmacéuticamente aceptable:en donde:A es un grupo de Ia fórmula (a) o (b): <EMI FILE="01013781_1" ID="1" IMF=JPEG >R1 representa un grupo carbocíclico C3-C7, alquilo C1-C8, alquenil C2-C6, o alquinil C2-C6, los últimos cuatro grupos opcionalmente substituidos por uno o más grupos substituyentes independientemente seleccionados entre átomos halógenos, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R10, un grupo arilo o heteroarilo que pueden ser opcionalmente substituidos por uno o más substituyentes independientemente seleccionados entre átomos de halógeno, grupos ciano, nitro, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR10, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R10, alquil C1-C6 o trifluorometilo;R2 representa un grupo de hidrógeno o un grupo carbocíclico C3-C7, alquil C1-C8, o alquenil C2-C6 o alquinil C2-C6, los últimos cuatros grupos pueden ser opcionalmente substituidos por uno o más grupos substituyentes independientemente seleccionados entre átomos de halógenos, -OR4, -NR5R6, -CONR5R6, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6 o -NR8SO2R9.R3 representa hidrógeno o alquil C2-C6, opcionalmente substituido por uno o mas grupos substituyentes independientemente seleccionados entre átomos halógenos, fenil, -OR10 y -NR11R12; - 2 -oR2 y R3 representan un anillo de 3-8 miembros que opcionalmente contiene uno o mas átomos seleccionados entre O, S NR8 y él mismo opcionalmente substituido por alquil C1-3, halógeno o OR4;R4 representa hidrógeno, un grupo alquil C1-C6 o fenil, los dos últimos pueden ser opcionalmente substituidos por uno o más grupos substituyentes independientemente seleccionados entre átomos halógenos, fenil OR11 y -NR12R13;R5 y R6 independientemente representan un átomo de hidrógeno o un grupo alquil C1-C6 o fenil, los últimos dos pueden ser opcionalmente substituidos por uno o más grupos substituyentes independientemente seleccionados entre átomos, halógenos, fenil, -OR14 y -NR15R16, -CONR15R16, -NR15COR16, -SO2NR15R16, -NR15SO2R16oR5 y R6 junto con el átomo de nitrógeno al que están adheridos, forman un sistema de anillo heterocíclico saturado de 4 a 7 miembros que opcionalmente comprende un heteroátomo adicional seleccionado entre átomos de oxígeno y nitrógeno, cuyo sistema de anillo puede ser opcionalmente substituido por uno o más grupos substituyentes independientemente seleccionados entre fenil, OR14, -COOR14, -NR15R16, -CONR15R16, -NR15COR16, -SO2NR15R16, NR15SO2R16, o alquil C1-C6, el mismo, opcionalmente substituido por uno o más substituyentes independientemente seleccionados entre átomos halógenos y grupos -NR15R16 y -OR17;R10 representa un grupo alquil C1-C6, o fenil, cada uno de los cuales puede ser opcionalmente substituido por uno o más grupos substituyentes independientemente seleccionados entre átomos halógenos, fenil, -OR17 y NR15R16;X es O, S o NR8Y es CR18R19Z es CR20 donde R20 representa un grupo alquil C1-C6 o fenil, cada uno de los cuales puede ser opcionalmente substituido por uno o más grupos substituyentes independientemente seleccionados entre átomos halógenos, fenil, -OR21 y -NR22R23, o un grupo acilo seleccionado entre CO2R21 o CONR22R23; ycada uno de R7, R8, R9, R11, R12, R13, R14, R15, R16, R17, R18, R19, R21, R22 y R23 independientemente representan un átomo de hidrógeno, un grupo alquil C1-C6, o fenil.
CO01013781A 2000-02-23 2001-02-21 Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados CO5290258A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0004128A GB2359551A (en) 2000-02-23 2000-02-23 Pharmaceutically active pyrimidine derivatives

Publications (1)

Publication Number Publication Date
CO5290258A1 true CO5290258A1 (es) 2003-06-27

Family

ID=9886153

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01013781A CO5290258A1 (es) 2000-02-23 2001-02-21 Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados

Country Status (33)

Country Link
US (2) US6875868B2 (es)
EP (1) EP1259512B1 (es)
JP (1) JP2003524012A (es)
KR (1) KR100795758B1 (es)
CN (1) CN1190437C (es)
AR (1) AR029805A1 (es)
AT (1) ATE250605T1 (es)
AU (1) AU782509B2 (es)
BG (1) BG107002A (es)
BR (1) BR0108600A (es)
CA (1) CA2400217C (es)
CO (1) CO5290258A1 (es)
CZ (1) CZ20022839A3 (es)
DE (1) DE60100851T2 (es)
DK (1) DK1259512T3 (es)
EE (1) EE200200461A (es)
ES (1) ES2206402T3 (es)
GB (1) GB2359551A (es)
HK (1) HK1050899A1 (es)
HU (1) HUP0204399A3 (es)
IL (2) IL151132A0 (es)
IS (1) IS6491A (es)
MX (1) MXPA02008233A (es)
NO (1) NO329898B1 (es)
NZ (1) NZ520355A (es)
PL (1) PL358004A1 (es)
PT (1) PT1259512E (es)
RU (1) RU2002125451A (es)
SK (1) SK12152002A3 (es)
TR (1) TR200302214T4 (es)
UA (1) UA72590C2 (es)
WO (1) WO2001062758A1 (es)
ZA (1) ZA200206590B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US6964967B2 (en) * 2000-12-11 2005-11-15 Amgen, Inc. Substituted pyrido[2,3-d]pyrimidines and methods for their use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
CA2590294A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP3098223A1 (en) * 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
JP2011528030A (ja) * 2008-07-16 2011-11-10 アストラゼネカ・アクチエボラーグ ピリミジルスルホンアミド誘導体およびケモカイン介在疾患処置のためのその使用
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
KR102052215B1 (ko) * 2011-06-01 2019-12-04 야누스 바이오테라퓨틱스, 인크. 신규한 면역 시스템 조절제
CN110420316A (zh) 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2924472A (en) 1957-06-27 1960-02-09 Gen Motors Corp Pipe joint seal
GB1009477A (en) 1962-02-13 1965-11-10 Smith Kline French Lab Novel process for preparing heterocyclic compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
BE668603A (es) 1964-08-20
US3859287A (en) * 1971-05-05 1975-01-07 Walter Wesley Parish Thiopteridines and process for producing same
DE2331223C2 (de) 1972-06-19 1984-11-22 Kohjin Co., Ltd., Tokio / Tokyo S-substituierte-2-Thioadenosine, deren 5'-Monophosphate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4120521A (en) 1975-08-28 1978-10-17 Rieber & Son Plastic-Industri A/S Combined mould element and sealing ring
EG12406A (en) 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
GB1600293A (en) 1977-02-04 1981-10-14 British Oceanics Ltd Sealing arrangements
US4188040A (en) 1977-04-06 1980-02-12 Firma WOCO Franz-Josef Wolf & Co. Sealing ring
DE2726959A1 (de) 1977-06-15 1979-01-18 Arlt Christian Dichteinsatz zum dichten verbinden von zwei rohren
FR2421899A1 (fr) 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
US4410528A (en) 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
DE3219522A1 (de) 1981-10-28 1983-12-01 Denso-Chemie Wedekind Kg, 5090 Leverkusen Steckmuffendichtung fuer rohre
FR2547888B1 (fr) 1983-06-22 1985-12-13 Sabla Sa Bague d'etancheite a implants pour tuyaux a emboitement
HU195822B (en) * 1985-12-30 1988-07-28 Gyogyszerkutato Intezet Process for producing new pyrimido/5,4-b//1,h/oxazine derivatives
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
SE8800348L (sv) 1988-02-03 1989-08-04 Forsheda Ab Taetningsring och verktyg foer framstaellning daerav
FR2659656B1 (fr) 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
DE4119767A1 (de) 1991-06-15 1992-12-17 Dresden Arzneimittel Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
JP3100469B2 (ja) * 1991-07-03 2000-10-16 中外製薬株式会社 乾癬治療剤
US5169161A (en) 1991-09-19 1992-12-08 Hail Mary Rubber Co., Inc. Symmetrical gasket for pipe joints
DE4134089C2 (de) 1991-10-15 1994-10-13 Dueker Eisenwerk Schubgesicherte Muffenverbindung
JPH05188994A (ja) 1992-01-07 1993-07-30 Sony Corp 騒音抑圧装置
DE4229609C2 (de) 1992-09-04 2003-05-08 Forsheda Stefa Gmbh Abdichtung zwischen zwei ineinandersteckbaren Teilen
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
DE69628804T2 (de) 1995-12-08 2003-12-18 Pfizer Substitutierte heterozyclische Derivate als CRF Antagonisten
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SE515033C2 (sv) 1995-12-27 2001-06-05 Forsheda Ab Tätningsanordning
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
AU2388697A (en) 1996-04-19 1997-11-12 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
ATE340176T1 (de) 1996-08-28 2006-10-15 Pfizer Substituierte 6,5-heterobicyclische-derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
DE69817393T2 (de) 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
US6423725B1 (en) 1998-01-19 2002-07-23 Pfizer Inc 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
CA2324550A1 (en) 1998-03-19 1999-09-23 Shigeyuki Chaki Arylpiperidine derivatives and use thereof
JP2002510695A (ja) 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
US5988695A (en) 1998-08-26 1999-11-23 S&B Technical Products, Inc. Pipe gasket with embedded ring
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
WO2000039129A1 (en) * 1998-12-28 2000-07-06 K.U. Leuven Research & Development Immunosuppressive effects of pteridine derivatives
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP2002536320A (ja) * 1999-02-02 2002-10-29 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント プテリジン誘導体の免疫抑制作用
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6142484A (en) 1999-04-15 2000-11-07 Vassallo Research & Development Corporation Composite multi-pressure gasket
AU5600100A (en) 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
OA12010A (en) * 1999-09-15 2006-04-19 Warner Lambert Co Pteridinones as kinase inhibitors.
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60023100T2 (de) 2000-01-05 2006-07-06 Pfizer Inc. Benzimidazol-Verbindungen zur Verwendung als ORL1-Rezeptor-Antagonisten
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
ATE255584T1 (de) 2000-02-11 2003-12-15 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359079A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
AU4274401A (en) 2000-03-24 2001-10-03 Meiji Seika Kaisha Diphenylalkylamine derivatives useful as opioid delta receptor agonists
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0004110L (sv) 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
KR20060120014A (ko) 2003-10-07 2006-11-24 아스트라제네카 아베 케모킨, 특히 ｃｘ3ｃｒ1 수용체 길항제로서 유용한 신규한2-치환된 4-아미노-티아졸로[4,5-ｄ]피리미딘
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
EP1844054A2 (en) 2004-12-17 2007-10-17 AstraZeneca AB Thiazolopyrimidine compounds for the modulation of chemokine receptor activity

Also Published As

Publication number Publication date
IL151132A (en) 2010-11-30
IS6491A (is) 2002-08-07
CA2400217A1 (en) 2001-08-30
CZ20022839A3 (cs) 2002-11-13
US20030055250A1 (en) 2003-03-20
PT1259512E (pt) 2004-02-27
KR20030005207A (ko) 2003-01-17
AR029805A1 (es) 2003-07-16
US6875868B2 (en) 2005-04-05
CA2400217C (en) 2009-02-17
BG107002A (bg) 2003-04-30
CN1404482A (zh) 2003-03-19
MXPA02008233A (es) 2004-04-05
GB0004128D0 (en) 2000-04-12
JP2003524012A (ja) 2003-08-12
KR100795758B1 (ko) 2008-01-21
TR200302214T4 (tr) 2004-01-21
NZ520355A (en) 2005-01-28
EP1259512A1 (en) 2002-11-27
DE60100851T2 (de) 2004-07-15
ATE250605T1 (de) 2003-10-15
RU2002125451A (ru) 2004-01-10
WO2001062758A1 (en) 2001-08-30
HUP0204399A2 (en) 2003-05-28
US20050171345A1 (en) 2005-08-04
EE200200461A (et) 2003-12-15
SK12152002A3 (sk) 2003-03-04
GB2359551A (en) 2001-08-29
BR0108600A (pt) 2002-11-12
PL358004A1 (en) 2004-08-09
CN1190437C (zh) 2005-02-23
DE60100851D1 (de) 2003-10-30
EP1259512B1 (en) 2003-09-24
AU782509B2 (en) 2005-08-04
NO20024005D0 (no) 2002-08-22
UA72590C2 (uk) 2005-03-15
NO20024005L (no) 2002-10-22
HUP0204399A3 (en) 2004-11-29
NO329898B1 (no) 2011-01-24
AU3431601A (en) 2001-09-03
HK1050899A1 (en) 2003-07-11
DK1259512T3 (da) 2003-12-29
US7579342B2 (en) 2009-08-25
IL151132A0 (en) 2003-04-10
ZA200206590B (en) 2003-11-17
ES2206402T3 (es) 2004-05-16

Similar Documents

Publication Publication Date Title
CO5290258A1 (es) Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR073687A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR067443A1 (es) Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central
AR055878A1 (es) Derivados de ciclopropanocarboxamida
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AR035371A1 (es) Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
AR019427A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa, procedimiento para su preparacion, su uso para la preparacion de medicamentos, composiciones farmaceuticas y compuestos intermediarios utiles para su preparacion
AR041186A1 (es) Moduladores del receptor de glucocorticoides
AR017177A1 (es) Compuesto derivados de 9-amino-3-ceto eritromicina, composiciones farmaceuticas, uso para la preparacion de un medicamento y procedimientos de preparacion.
CO5261632A1 (es) Inhibidores de la recaptacion de monoamidas para el tratamiento del snc
AR040498A1 (es) Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias
AR048934A1 (es) Morfolinas
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR018452A1 (es) Compuestos antibioticos de oxazolidinona sustituida, proceso para su preparacion, metodo para producir un efecto antibacteriano, composicionesfarmaceuticas que los contienen y su uso para preparar medicamentos
AR040700A1 (es) Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas
AR053311A1 (es) Macrolonas - quinolonas amino sustituidas
AR045040A1 (es) Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
BR1100931A (pt) Compostos derivados de aril-heteroaril carbinóis, processos para a preparação dos compostos, composições farmacêuticas, e, uso dos compostos derivados de aril-heteroaril carbinóis
AR035235A1 (es) Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento

Legal Events

Date Code Title Description
FC Application refused